PROOF Centre

Name

PROOF Centre

Legal name

Centre of Excellence for the Prevention of Organ Failure

Website

https://proofcentre.ca

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Clinical Biomarker Research and Development

NAICS

Medical Laboratories (621511), Other Scientific and Technical Consulting Services (541690), Testing Laboratories and Services (541380)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

akta.pro secondary industries

Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Biomarker development
• Omics diagnostics
• Transplant rejection testing
• Clinical biomarker research
• Blood-based diagnostics

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Funding and Grants: As a not-for-profit organization established in 2008 through Networks of Centres of Excellence funding, PROOF Centre receives government funding for biomarker research programs.
2. Industry Partnerships and Collaborations: Collaborative research agreements with pharmaceutical and biotech companies (AstraZeneca, OriGene, HTG Molecular Diagnostics) for biomarker development and validation services.
3. Service Contracts: Provides expertise in computation, 'omic science and biomarker workflow to organizations seeking to discover and implement blood-based molecular biomarkers through service contracts.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

PROOF Centre discovers, develops, and clinically validates blood-based omics biomarker tests for heart, lung, and kidney disease, including the HEARTBiT transcriptomic assay for heart transplant rejection, COPD exacerbation prediction tests, chronic kidney disease prognostic tests, and allergy/asthma biomarker panels. It also provides a Biomarker Development Service offering computational, multi-omics, and clinical workflow expertise to pharmaceutical, biotech, and diagnostic organizations under collaborative research and service contracts.

Product overview

The PROOF Centre is a not-for-profit biomarker development organization that functions as a multi-product research and service provider rather than a single commercial product company. Its core offerings include a suite of disease-specific biomarker programs — HEARTBiT (heart transplant rejection transcriptomic test), COPD biomarker program (lung attack prediction), chronic kidney disease prognostic test, and allergy vaccine biomarker panels — all delivered as blood-based 'omics tests. These are complemented by a Biomarker Development Service providing computational, 'omics science, and biomarker workflow expertise to external organizations. The organization also maintains a Patents Program and Spotlight Series. The programs are supported by proprietary computational pipelines including DIABLO multi-omics integration, Enumerateblood for blood cell composition estimation, and SABRE for gene module stability assessment.

Differentiator

Problem solved

Functional benefit

Products and services

• Biomarker Development Service
• HEARTBiT (Heart Allograft Rejection Transcriptomic Biomarker Test)
• Chronic Obstructive Pulmonary Disease (COPD) Biomarker Program
• Heart Transplant Rejection Biomarker Program
• Chronic Kidney Disease (CKD) Prognostic Biomarker Test
• Allergy Vaccine Biomarker Panel

Quantifiable outcome

• Heart transplant patients currently require 12 invasive biopsies per year in first year post-transplant; blood test aims to reduce this burden
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• AstraZenecacoreStrategic or Co-development Partner · 11 February 2016Partnership with AstraZeneca and CanPREDDICT to develop blood test predicting chronic kidney disease progression. Uses PROOF Centre's omics biomarker development pipeline on CanPREDDICT cohort data.
• Centre for Drug Research and Development (CDRD)coreStrategic or Co-development Partner · 28 November 2013Preferred Collaboration Agreement between two CECRs to align expertise in biomarker solutions with drug development capabilities. Focus on companion diagnostics and personalized medicine.
• Jain FoundationminorStrategic or Co-development Partner · 16 October 2013Collaboration to identify blood-based biomarkers for LGMD2B/Miyoshi Muscular Dystrophy. Compares blood samples from affected individuals with healthy controls to identify disease biomarkers.
• HTG Molecular DiagnosticscoreTechnology or Integration · 25 September 2013Partnership for clinical validation of heart transplant rejection blood test using HTG Edge System at St. Paul's Hospital. HTG provides automated RNA analysis platform for molecular biomarker test validation. Blood test intended to replace invasive biopsies for heart transplant monitoring.
• MRM ProteomicscoreTechnology or Integration · 26 September 2012Partnership to create end-to-end solution for using protein signatures in blood to predict onset and progression of heart, lung, and kidney disease. PROOF Centre provides computational pipeline while MRM provides mass spectrometry expertise.
• AllerGen NCEcoreStrategic or Co-development Partner · 20 September 2012Collaboration between two Networks of Centres of Excellence to develop blood tests for allergic asthma clinical trials. Uses AllerGen Clinical Investigator Collaborative samples for biomarker discovery.
• IO InformaticscoreTechnology or Integration · 11 September 2012Collaboration to develop web-based software application for clinicians to use with PROOF Centre blood tests. Application provides risk scores and clinical recommendations using gene and protein expression data.
• OriGene TechnologiescoreTechnology or Integration · 19 July 2012Multi-year collaboration to develop blood-based protein assays for heart and kidney transplantation monitoring. OriGene leverages its UltraMAB antibodies and Luminex multiplex assay development expertise for diagnostic assay creation.
• Adiga Life SciencesminorStrategic or Co-development Partner · 8 April 2012Joint biomarker discovery project to identify blood-based proteomic and genomic biomarkers for monitoring peptide allergy vaccine effectiveness in allergic rhinitis patients.
• University of British ColumbiacoreStrategic or Co-development Partner · 8 March 2008Host institution for PROOF Centre. Provides academic infrastructure, research expertise, and access to faculty including researchers at Centre for Heart Lung Innovation.
• Providence Health CarecoreStrategic or Co-development Partner · 8 March 2008Co-host institution with UBC. Clinical operations anchored at St. Paul's Hospital providing access to patient cohorts and clinical trial infrastructure.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Broad Institute: The Broad Institute is a leading academic multi-omics research organization operating biomarker and disease genomics programs at scale; it competes for talent, grants, and publication visibility relevant to PROOF's multi-omics biomarker discovery and validation work.
• CareDx: CareDx is an established commercial diagnostics incumbent leading the heart transplant rejection monitoring market with AlloMap and AlloSure; its commercial scale and regulatory infrastructure represent a broad incumbent against PROOF's HEARTBiT program and transplant biomarker commercial pathway.
• HTG Molecular Diagnostics: HTG Molecular provides the HTG EdgeSeq NGS-based RNA expression platform used in PROOF's heart transplant rejection clinical validation; HTG is a broader diagnostics incumbent that supplies the underlying analyte measurement technology for one of PROOF's flagship programs.
• BGI Genomics: BGI operates large-scale genomic and multi-omic biomarker discovery and clinical services globally, providing a broad incumbent comparable to PROOF's integration of genomic, proteomic, metabolomic and clinical data for biomarker development.

Emerging players

• Berg Health: Berg Health uses an AI-driven multi-omics platform for biomarker-guided drug discovery, partially overlapping with PROOF's companion diagnostics and pharma partnership focus (e.g., AstraZeneca CKD work) at the drug-development interface.

Regional players

• BC Cancer Research Centre: BC Cancer Research Centre is a Vancouver-based academic research organization with overlapping multi-omics, bioinformatics and precision-medicine capabilities, making it a regional peer for talent, grant funding, and biomarker development collaborations.

Direct peers

• Metabolon: Metabolon is a direct peer offering metabolomics-based biomarker discovery services and clinical assays using high-throughput mass spectrometry — comparable to PROOF Centre's metabolomics arm of its multi-omics pipeline and its MRM Proteomics partnership for heart, lung, and kidney disease biomarkers.
• SOPHiA GENETICS: SOPHiA GENETICS provides AI-driven multi-omics data analysis and biomarker interpretation through its SOPHiA DDM platform, directly comparable to PROOF's machine-learning driven multi-omics integration approach for diagnostic and prognostic biomarker development.
• Cedars-Sinai Smidt Heart Institute: The Smidt Heart Institute runs a parallel academic clinical research program on heart transplant rejection biomarkers and cardiovascular omics, overlapping directly with PROOF's HEARTBiT transcriptomic assay and heart transplant monitoring program.
• SomaLogic: SomaLogic operates a proteomics biomarker discovery and clinical assay platform using aptamer-based protein measurement. It overlaps directly with PROOF's protein biomarker discovery work for transplant rejection, COPD and CKD across multiple disease areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/proofcentre
• LinkedInlinkedin.com/company/proof-centre

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PROOF Centre